Pelthos Therapeutics (NYSEAMERICAN:PTHS) Releases Earnings Results

Pelthos Therapeutics (NYSEAMERICAN:PTHS) posted its earnings results on Thursday. The company reported ($3.09) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $10.91 million during the quarter.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• Pelthos said ZELSUVMI revenue and prescriptions continued to accelerate, with Q1 2026 net product revenue rising to $10.7 million and prescription units up 25% sequentially to 7,884.
• The company highlighted broadening adoption, with unique prescribers increasing to 3,228 and management saying repeat prescribing is trending higher as more physicians continue to write scripts.
• Commercial access remains strong, with Pelthos reporting 59% commercial insurance coverage and 99% Medicaid coverage for ZELSUVMI, supported by a large PBM contract that reduced friction and helped drive utilization.
• Management said it has expanded the sales force from 50 to 64 reps and will add three more territories in June, while planning launches of Xepi in early 2027 and Xeglyze in mid-2027 to leverage the same commercial infrastructure.
• The balance sheet improved after closing a $50 million term debt loan and drawing $30 million, leaving the company with $32 million of cash at quarter-end and management saying it believes it has sufficient runway to execute its plan.

Pelthos Therapeutics Trading Down 4.1%

Shares of NYSEAMERICAN PTHS traded down $1.14 during mid-day trading on Friday, reaching $26.55. The company had a trading volume of 6,483 shares, compared to its average volume of 12,514. The stock has a 50 day simple moving average of $23.46. Pelthos Therapeutics has a 52-week low of $9.00 and a 52-week high of $54.29. The company has a current ratio of 2.05, a quick ratio of 1.15 and a debt-to-equity ratio of 0.81. The stock has a market cap of $89.21 million, a PE ratio of -1.28 and a beta of 3.29.

Analyst Upgrades and Downgrades

Several brokerages have commented on PTHS. Piper Sandler assumed coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They issued an “overweight” rating and a $48.00 price target for the company. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price for the company. Roth Mkm reduced their price target on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Oppenheimer lifted their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Pelthos Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.80.

Institutional Trading of Pelthos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ikarian Capital LLC grew its stake in Pelthos Therapeutics by 309.5% during the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after buying an additional 193,307 shares during the last quarter. Boothbay Fund Management LLC grew its position in shares of Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the last quarter. J. Goldman & Co LP acquired a new position in shares of Pelthos Therapeutics in the 4th quarter valued at $2,418,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Pelthos Therapeutics in the fourth quarter valued at about $1,085,000. Finally, Diadema Partners LP lifted its position in Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares during the period. 77.96% of the stock is owned by hedge funds and other institutional investors.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).